过敏性休克生物标志物:现状与未来。

IF 2.6 Q2 ALLERGY European annals of allergy and clinical immunology Pub Date : 2024-11-01 Epub Date: 2024-06-26 DOI:10.23822/EurAnnACI.1764-1489.350
A Pampura, N Esakova, S Zimin, E Filippova
{"title":"过敏性休克生物标志物:现状与未来。","authors":"A Pampura, N Esakova, S Zimin, E Filippova","doi":"10.23822/EurAnnACI.1764-1489.350","DOIUrl":null,"url":null,"abstract":"<p><strong>Summary: </strong>Anaphylaxis is a severe, rapidly developing, and life-threatening systemic hypersensitivity reaction. The diagnosis of anaphylaxis is primarily clinical. Numerous studies on the mechanisms and the biomarkers of the disease are initiated every year. The biomarkers of anaphylaxis may become an important tool for the diagnosis, prevention, repeated risk assessment, severity stratification, and new therapeutic strategies for treatment of the disease. Various immune and non-immune mediators produced and released by effector cell populations are currently considered as biomarkers of anaphylaxis. Here, we review the current data on potential biomarkers of anaphylaxis and the possibilities and perspectives for their use in future clinical practice.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":"243-251"},"PeriodicalIF":2.6000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Anaphylaxis biomarkers: present and future.\",\"authors\":\"A Pampura, N Esakova, S Zimin, E Filippova\",\"doi\":\"10.23822/EurAnnACI.1764-1489.350\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Summary: </strong>Anaphylaxis is a severe, rapidly developing, and life-threatening systemic hypersensitivity reaction. The diagnosis of anaphylaxis is primarily clinical. Numerous studies on the mechanisms and the biomarkers of the disease are initiated every year. The biomarkers of anaphylaxis may become an important tool for the diagnosis, prevention, repeated risk assessment, severity stratification, and new therapeutic strategies for treatment of the disease. Various immune and non-immune mediators produced and released by effector cell populations are currently considered as biomarkers of anaphylaxis. Here, we review the current data on potential biomarkers of anaphylaxis and the possibilities and perspectives for their use in future clinical practice.</p>\",\"PeriodicalId\":11890,\"journal\":{\"name\":\"European annals of allergy and clinical immunology\",\"volume\":\" \",\"pages\":\"243-251\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European annals of allergy and clinical immunology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.23822/EurAnnACI.1764-1489.350\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/26 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European annals of allergy and clinical immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23822/EurAnnACI.1764-1489.350","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

摘要

摘要: 过敏性休克是一种严重、发展迅速、危及生命的全身性超敏反应。过敏性休克的诊断主要依靠临床。每年都有大量关于过敏性休克发病机制和生物标志物的研究。过敏性休克的生物标志物可能成为诊断、预防、重复风险评估、严重程度分层和治疗该疾病的新疗法的重要工具。目前,效应细胞群产生和释放的各种免疫和非免疫介质被认为是过敏性休克的生物标志物。在此,我们回顾了过敏性休克潜在生物标志物的现有数据以及在未来临床实践中使用这些生物标志物的可能性和前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Anaphylaxis biomarkers: present and future.

Summary: Anaphylaxis is a severe, rapidly developing, and life-threatening systemic hypersensitivity reaction. The diagnosis of anaphylaxis is primarily clinical. Numerous studies on the mechanisms and the biomarkers of the disease are initiated every year. The biomarkers of anaphylaxis may become an important tool for the diagnosis, prevention, repeated risk assessment, severity stratification, and new therapeutic strategies for treatment of the disease. Various immune and non-immune mediators produced and released by effector cell populations are currently considered as biomarkers of anaphylaxis. Here, we review the current data on potential biomarkers of anaphylaxis and the possibilities and perspectives for their use in future clinical practice.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.00
自引率
0.00%
发文量
102
期刊最新文献
Comparison of the characteristics of patients with chronic urticaria receiving standard- or high-dose omalizumab. Early markers of baked milk and egg tolerance in young children with IgE-mediated immediate reactions. Provocation test on stairs: a new accessible method to cholinergic urticaria diagnosis. Rhinitis or asthma among adults as associated factors with symptoms of depression. Survey on the attitude of Italian allergologists concerning the topical nasal therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1